Source: International Congress 2015 – Lung cancer therapy: clinical trials
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Vítězslav Kolek (Olomouc, Czech Republic), Vitezslav Kolek, Ivona Grygarkova, Leona Koubkova, Tereza Janaskova, Jana Skrickova, Jaromir Roubec. Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study. Eur Respir J 2015; 46: Suppl. 59, 4838

Member's Comments

No comment yet.

Related content which might interest you: Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 12s Year: 2005 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Reduction of peak oxygen consumption in patients with non-small cell lung cancer treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020 Accelereated hyperfractionated radiotherapy with uneven crushing daily dose in chemoradiation treatment of inoperable non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006